The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion.
Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The...read more
Eight IPOs and nine SPACs entered the public markets this past week led by BigCommerce (BIGC), which soared 201% in the best first-day pop for an IPO over $100 million in 15 years.
E-commerce platform BigCommerce (BIGC)...read more
Freeline Therapeutics, a Phase 1/2 biotech developing gene therapies for hemophilia and rare diseases, raised $159 million by offering 8.8 million shares at $18, the high end of the range of $16 to $18. The Stevenage, UK-based company offered 1.5 million more...read more
Freeline Therapeutics, a Phase 1/2 biotech developing gene therapies for rare diseases, announced terms for its IPO on Monday. The Stevenage, UK-based company plans to raise $125 million by offering 7.4 million ADSs at a price range of $16 to $18. At the...read more
US IPO Week Ahead: Canadian IT and German chemicals lead a diverse 9 IPO week
The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion. Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The...read more
US IPO Weekly Recap: BigCommerce’s 201% first-day pop breaks records in an 8 IPO week
Eight IPOs and nine SPACs entered the public markets this past week led by BigCommerce (BIGC), which soared 201% in the best first-day pop for an IPO over $100 million in 15 years. E-commerce platform BigCommerce (BIGC)...read more
Gene therapy biotech Freeline Therapeutics prices upsized US IPO at $18 high end
Freeline Therapeutics, a Phase 1/2 biotech developing gene therapies for hemophilia and rare diseases, raised $159 million by offering 8.8 million shares at $18, the high end of the range of $16 to $18. The Stevenage, UK-based company offered 1.5 million more...read more
Gene therapy biotech Freeline Therapeutics sets terms for $125 million US IPO
Freeline Therapeutics, a Phase 1/2 biotech developing gene therapies for rare diseases, announced terms for its IPO on Monday. The Stevenage, UK-based company plans to raise $125 million by offering 7.4 million ADSs at a price range of $16 to $18. At the...read more